The Melanoma Content Hub Channel

Dr. Polsky on the Clinical Validity of ctDNA in BRAF-Mutant Melanoma

In this interview, David Polsky, MD, PhD, shares details about his advanced laboratory tumor detection technology and the study results presented at ASCO 2020. Dr. Polsky suggests that testing for circulating tumor DNA is the most precise methodology available and that his highest ever reported detection rate is evidence to support this conclusion.

Learn more by clicking here.

More in Melanoma Content Hub

►

Chipping Away at the Surface of Melanoma Treatment: Narrowing Down Therapies

Melanoma Content Hub

Rahul Seth, DO, assistant professor of medicine at Upstate University Hospital, provides recommendations for the treatment of melanoma. For patients with unresectable melanoma, Dr. Seth recommends a combination of nivolumab...

► 1:45

Dr. Glitza Olivia on the Prognosis of Melanoma Brain Metastases

Melanoma Content Hub

Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses...

►

Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure

Melanoma Content Hub

Gal Markel, MD, PhD, chief scientist and senior oncologist at Sheba Medical Center, discusses the use of fecal microbiota transplant (FMT) for melanoma patients nonresponsive to PD-1 inhibition. FMT patients...

►

Investigators Present Updated Results of the OpACIN Trial for Melanoma

Melanoma Content Hub

Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, provides a three year update for the first clinical trial for the assessment of...